Nothing Special   »   [go: up one dir, main page]

AR107154A1 - Estimuladores de guanilato ciclasa soluble - Google Patents

Estimuladores de guanilato ciclasa soluble

Info

Publication number
AR107154A1
AR107154A1 ARP160103930A ARP160103930A AR107154A1 AR 107154 A1 AR107154 A1 AR 107154A1 AR P160103930 A ARP160103930 A AR P160103930A AR P160103930 A ARP160103930 A AR P160103930A AR 107154 A1 AR107154 A1 AR 107154A1
Authority
AR
Argentina
Prior art keywords
alkyl
formula
cycloalkyl
ring
subscript
Prior art date
Application number
ARP160103930A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR107154A1 publication Critical patent/AR107154A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos o sus sales farmacéuticamente aceptables pueden modular la producción corporal de guanosín monofosfato cíclico (“GMPc”) y son generalmente adecuados para el tratamiento y la prevención de enfermedades que están asociadas con un equilibrio de GMPc perturbado. También proporciona composiciones farmacéuticas que comprenden compuestos de fórmula (1) o sales farmacéuticamente aceptables de los mismos. También se refiere a procedimientos para el uso de los compuestos o sus sales farmacéuticamente aceptables en el tratamiento y la prevención de las enfermedades mencionadas anteriormente y para la preparación de productos farmacéuticos para este fin. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en la que: X es C(H) o N; cada R¹ es independientemente halo, hidroxilo, alquilo C₁₋₃, cicloalquilo C₃₋₆ u -O-alquilo C₁₋₃; R² es: (a) alquilo C₁₋₆, estando dicho alquilo C₁₋₆ de R² sin sustituir o sustituido con 1 a 6 restos seleccionados independientemente de fluoro u -O-alquilo C₁₋₃; (b) anillo C², siendo el anillo C²: (i) cicloalquilo C₃₋₁₂; (ii) fenilo; (iii) un heteroarilo monocíclico de 5 ó 6 miembros que contiene de 1 a 2 heteroátomos seleccionados de N, O ó S; o (iv) un heterociclilo monocíclico de 5 ó 6 miembros que contiene de 1 a 2 heteroátomos seleccionados de N, O ó S; estando el anillo C² sin sustituir o sustituido con 1 a 3 restos seleccionados independientemente de halo, ciano, alquilo C₁₋₃, -O-alquilo C₁₋₃ u oxo; R⁴ es alquilo C₁₋₆, CF₃ o cicloalquilo C₃₋₆; el anillo C³ es: (a) fenilo; (b) un heteroarilo monocíclico de 5 ó 6 miembros o un heteroarilo bicíclico de 9 a 10 miembros que contiene de 1 a 3 heteroátomos seleccionados de N, O ó S; (c) un heterociclilo monocíclico de 5 ó 6 miembros que contiene de 1 a 3 heteroátomos seleccionados de N, O ó S; (d) cicloalquilo C₃₋₆; seleccionándose cada Rᵃ independientemente de halo, ciano, alquilo C₁₋₃, -O-alquilo C₁₋₃, oxo o hidroxilo; Y es: (a) un enlace; (b) representa un grupo de la fórmula (2), en la que RY¹ y RY² son independientemente H, alquilo C₁₋₃, hidroxilo, fluoro, hidroxialquilo C₁₋₃ o amino; o como alternativa RY¹ y RY², conjuntamente con el átomo de carbono al que están unidos forman un cicloalquilo C₃₋₆; RY³ y RY⁴ son independientemente H, alquilo C₁₋₃, hidroxilo, fluoro o hidroxialquilo C₁₋₃ ; o como alternativa RY³ y RY⁴, conjuntamente con el átomo de carbono al que están unidos, forman un cicloalquilo C₃₋₆; (c) un grupo de la fórmula (3); o (d) un anillo AH, siendo el anillo AH cicloalquilo C₃₋₆ o fenilo, en lo que el anillo AH está sin sustituir o sustituido con 1 a 3 restos seleccionados independientemente de halo o alquilo C₁₋₃; (e) un grupo -CH=CH-; o (f) un grupo de fórmula (4); Z es: (a) -CO₂H; (b) -C(O)N(H)OH; (c) un resto de fórmula (5); (d) un resto de fórmula (6); (e) un resto de fórmula (7); (f) -SO₃H; (g) -P(=O)(OH)₂ o (h) -C(O)N(H)S(O)₂CH₃; el subíndice m es 0, 1 ó 2; el subíndice p es 0, 1, 2 ó 3; el subíndice q es 0 ó 1; el subíndice r1 es 0, 1, 2, 3 ó 4; y el subíndice r2 es 0 ó 1.
ARP160103930A 2015-12-22 2016-12-20 Estimuladores de guanilato ciclasa soluble AR107154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/098251 WO2017107052A1 (en) 2015-12-22 2015-12-22 Soluble guanylate cyclase stimulators

Publications (1)

Publication Number Publication Date
AR107154A1 true AR107154A1 (es) 2018-03-28

Family

ID=57758775

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103930A AR107154A1 (es) 2015-12-22 2016-12-20 Estimuladores de guanilato ciclasa soluble

Country Status (39)

Country Link
US (2) US10030027B2 (es)
EP (1) EP3394067B1 (es)
JP (1) JP6454448B2 (es)
KR (1) KR102191312B1 (es)
CN (1) CN108738320B (es)
AR (1) AR107154A1 (es)
AU (1) AU2016377364B2 (es)
BR (1) BR112018012579B8 (es)
CA (1) CA3009193C (es)
CL (1) CL2018001671A1 (es)
CO (1) CO2018006300A2 (es)
CR (1) CR20180330A (es)
CY (1) CY1123173T1 (es)
DK (1) DK3394067T3 (es)
DO (1) DOP2018000153A (es)
EA (1) EA036445B1 (es)
EC (1) ECSP18054606A (es)
ES (1) ES2794654T3 (es)
HK (1) HK1255028A1 (es)
HR (1) HRP20200857T1 (es)
HU (1) HUE049941T2 (es)
IL (1) IL260020B (es)
LT (1) LT3394067T (es)
ME (1) ME03748B (es)
MX (2) MX2018007728A (es)
MY (1) MY194021A (es)
NI (1) NI201800069A (es)
PE (1) PE20181802A1 (es)
PH (1) PH12018501342A1 (es)
PL (1) PL3394067T3 (es)
PT (1) PT3394067T (es)
RS (1) RS60344B1 (es)
SG (1) SG11201805272XA (es)
SI (1) SI3394067T1 (es)
SV (1) SV2018005715A (es)
TN (1) TN2018000219A1 (es)
TW (1) TWI724079B (es)
UA (1) UA122264C2 (es)
WO (2) WO2017107052A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245264B2 (en) 2015-05-27 2019-04-02 Merck Sharp & Dohme Corp. Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
EP3310782B1 (en) 2015-05-28 2021-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MD3394033T2 (ro) 2015-12-22 2021-04-30 Incyte Corp Compuși heterociclici ca imunomodulatori
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
EP3458063A4 (en) 2016-05-18 2020-02-26 Merck Sharp & Dohme Corp. METHODS OF USING TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR FIBROTIC DISORDERS
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
TWI798192B (zh) 2016-12-22 2023-04-11 美商英塞特公司 免疫調節劑化合物及使用方法
UA126394C2 (uk) 2016-12-22 2022-09-28 Інсайт Корпорейшн Похідні бензоксазолу як імуномодулятори
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US11242335B2 (en) 2017-04-11 2022-02-08 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CN112135824B (zh) 2018-03-30 2024-11-05 因赛特公司 作为免疫调节剂的杂环化合物
US20210052528A1 (en) 2018-04-30 2021-02-25 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
US20220128561A1 (en) 2019-01-17 2022-04-28 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
JP2022544189A (ja) 2019-08-09 2022-10-17 インサイト・コーポレイション Pd-1/pd-l1阻害剤の塩
CN115175734B (zh) 2019-09-30 2024-04-19 因赛特公司 作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of pd-1/pd-l1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備pd-1/pd-l1抑制劑以及其鹽及結晶形式之方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP0970095B1 (en) 1997-03-07 2003-10-29 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19744027A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6489476B1 (en) 1998-09-09 2002-12-03 Metabasis Therapeutics, Inc. Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase
DE60128475T2 (de) 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
CA2434491A1 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
AU2003260085B2 (en) 2002-08-29 2008-09-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004020408A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004066963A2 (en) 2003-01-17 2004-08-12 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
KR101404781B1 (ko) 2007-06-28 2014-06-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치의 제조 방법
US20100179173A1 (en) 2007-06-28 2010-07-15 Daniel Guay Substituted fused pyrimidines as antagonists of gpr105 activity
EP2178537A4 (en) 2007-07-19 2011-08-17 Merck Sharp & Dohme BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
CN101939053A (zh) 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
AU2009322836B2 (en) * 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
AU2010218224B2 (en) 2009-02-26 2013-06-27 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2575473B1 (en) * 2010-05-27 2016-01-20 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN106977530A (zh) 2010-07-09 2017-07-25 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP6005134B2 (ja) 2011-04-21 2016-10-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH フルオロアルキル置換ピラゾロピリジンおよびその使用
EP2705037B1 (de) 2011-05-06 2016-06-22 Bayer Intellectual Property GmbH Substituierte imidazopyridine und imidazopyridazine und ihre verwendung
RU2014103960A (ru) 2011-07-06 2015-08-20 Байер Интеллектуэль Проперти Гмбх Гетероарилзамещенные пиразолопиридины и их применение в качестве стимуляторов растворимой гуанилатциклазы
CN104039784B (zh) * 2011-09-02 2017-08-22 拜耳知识产权有限责任公司 取代的增环嘧啶及其用途
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
CA2917682A1 (en) 2013-07-10 2015-01-15 Bayer Pharma Aktiengesellschaft Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
WO2015088886A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3079701B1 (en) 2013-12-11 2021-08-11 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CN107406421A (zh) 2014-09-17 2017-11-28 铁木医药有限公司 sGC刺激物
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
US10245264B2 (en) 2015-05-27 2019-04-02 Merck Sharp & Dohme Corp. Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
EP3310782B1 (en) 2015-05-28 2021-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
CA3006764A1 (en) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
JP7098214B2 (ja) 2016-02-01 2022-07-11 サイクレリオン・セラピューティクス,インコーポレーテッド 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用

Also Published As

Publication number Publication date
TN2018000219A1 (en) 2019-10-04
LT3394067T (lt) 2020-06-10
CN108738320B (zh) 2021-11-19
IL260020A (en) 2018-07-31
MY194021A (en) 2022-11-08
MX2020011080A (es) 2020-11-06
ECSP18054606A (es) 2018-12-31
IL260020B (en) 2021-05-31
AU2016377364A1 (en) 2018-06-14
BR112018012579B1 (pt) 2023-10-24
SV2018005715A (es) 2018-10-19
US10030027B2 (en) 2018-07-24
US20170174693A1 (en) 2017-06-22
CA3009193C (en) 2020-09-15
SG11201805272XA (en) 2018-07-30
CN108738320A (zh) 2018-11-02
CO2018006300A2 (es) 2018-07-10
TW201734017A (zh) 2017-10-01
WO2017107052A1 (en) 2017-06-29
HRP20200857T1 (hr) 2020-11-13
PT3394067T (pt) 2020-06-02
EA201891303A1 (ru) 2018-11-30
US20180305366A1 (en) 2018-10-25
PH12018501342A1 (en) 2019-02-18
ME03748B (me) 2021-04-20
DOP2018000153A (es) 2018-11-30
SI3394067T1 (sl) 2020-07-31
BR112018012579A2 (pt) 2018-12-04
ES2794654T3 (es) 2020-11-18
NI201800069A (es) 2018-10-05
MX2018007728A (es) 2018-08-15
EP3394067B1 (en) 2020-04-01
WO2017112617A1 (en) 2017-06-29
HUE049941T2 (hu) 2020-11-30
PL3394067T3 (pl) 2020-08-24
TWI724079B (zh) 2021-04-11
CR20180330A (es) 2018-08-21
EA036445B1 (ru) 2020-11-11
RS60344B1 (sr) 2020-07-31
KR20180095904A (ko) 2018-08-28
BR112018012579B8 (pt) 2023-10-24
PE20181802A1 (es) 2018-11-19
US10428076B2 (en) 2019-10-01
CY1123173T1 (el) 2021-10-29
CA3009193A1 (en) 2017-06-29
JP2018538333A (ja) 2018-12-27
HK1255028A1 (zh) 2019-08-02
JP6454448B2 (ja) 2019-01-16
AU2016377364B2 (en) 2019-02-14
DK3394067T3 (da) 2020-06-15
UA122264C2 (uk) 2020-10-12
CL2018001671A1 (es) 2018-08-03
KR102191312B1 (ko) 2020-12-15
EP3394067A1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
AR107154A1 (es) Estimuladores de guanilato ciclasa soluble
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
UY38296A (es) Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
AR094300A1 (es) Derivados de quinolonas
AR112834A1 (es) Derivados de rapamicina
MD3601283T2 (ro) Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA201591457A8 (ru) Терапевтические соединения
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA201890221A1 (ru) Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
HN2011003482A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
AR099867A1 (es) Compuestos imidazobenzotiazolo fusionados
EA201692270A1 (ru) Производные нафтиридиндиона
TR201819805T4 (tr) Flavaglin türevleri̇.
AR101290A1 (es) Inhibidores de aldosterona sintasa